Genzyme Corporation

Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder [Press Release]
Business Wire | 4 days 19 hours 45 minutes ago
Genzyme Corporation (Nasdaq: GENZ) today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer carbonate). Based on these results, the company is not planning to pursue further clinical development of the APB. Genzyme was seekin...

Genzyme Receives Complete Response Letter on Lumizyme Application [Press Release]
Business Wire | 6 days 17 hours 23 minutes ago
Genzyme Corporation (Nasdaq: GENZ) announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved. Genzyme believes the other elements of the Lumizyme review, such as the Risk Evaluation and...

Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA [Press Release]
Business Wire | 5 days 17 hours 10 minutes ago
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions. The study met its primary endpoint in an intent-to-treat analysis, with a 25 percent reduction in LDL-cholesterol after 26 weeks of treatment, vs. 3 percent for placebo (p<0.001) which constitutes an average reduction great...

First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease [Press Release]
Business Wire | 33 days 13 hours 39 minutes ago
Genzyme Corporation (NASDAQ: GENZ) today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.

Scientists Name Genzyme a Top Employer [Press Release]
Business Wire | 39 days 15 hours 34 minutes ago
Genzyme Corporation (Nasdaq: GENZ) announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

Targeted Genetics Corporation Reports Third Quarter 2009 Financial Results [Press Release]
Business Wire | 6 days 10 hours 25 minutes ago
Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the third quarter ended September 30, 2009.

Hagens Berman Announces Class-Action Lawsuit Filed Against Genzyme Corporation [Press Release]
PRNewswire | 110 days 12 hours 9 minutes ago
...Action Lawsuit Filed Against Genzyme Corporation PRNewswire SEATTLE Aug. 4...District of Massachusetts against Genzyme Corporation alleging the company issued...serve as lead plaintiff. Genzyme Corporation, a biotechnology company...

BioMarin Announces Third Quarter 2009 Financial Results [Press Release]
PRNewswire | 25 days 6 hours 40 minutes ago
NOVATO, Calif., Oct. 28 /PRNewswire-FirstCall/ --

Zacks Sell List Highlights: Pinnacle Financial Partners, Marten Transport Ltd., Genzyme Corporation and MDS Inc. [Press Release]
Business Wire | 30 days 10 hours 40 minutes ago
Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List – Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Pinnacle Financial Partners (Nasdaq: PNFP) and Marten Transport Ltd. (Nasdaq: MRTN). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Genzyme Corporation (Nasdaq: GENZ) and MDS Inc. (NYSE: MDZ). To see the full Zacks #5 Rank List - Stocks to Sell Now visit: http://at.z...

Phase Forward to Host Eighth Annual International Users Conference, November 3-5, Boston [Press Release]
Business Wire | 20 days 17 hours 40 minutes ago
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will host its eighth annual International Users Conference (IUC) this week. Under the theme “Powering More Possibilities,” the conference will be held at the Sheraton Boston Hotel in Boston.